EP1250431A4 - Modulierung der genexpression bei der bildung von fett-atherosklerotischen schädigungen - Google Patents

Modulierung der genexpression bei der bildung von fett-atherosklerotischen schädigungen

Info

Publication number
EP1250431A4
EP1250431A4 EP01905039A EP01905039A EP1250431A4 EP 1250431 A4 EP1250431 A4 EP 1250431A4 EP 01905039 A EP01905039 A EP 01905039A EP 01905039 A EP01905039 A EP 01905039A EP 1250431 A4 EP1250431 A4 EP 1250431A4
Authority
EP
European Patent Office
Prior art keywords
modulation
formation
gene expression
atherosclerotic lesions
fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01905039A
Other languages
English (en)
French (fr)
Other versions
EP1250431A2 (de
Inventor
Amedeo Leonardi
Abraham Sartani
James R Glass
J Gregor Sutcliffe
Karl W Hasel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROME Inc
Original Assignee
Digital Gene Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digital Gene Technologies Inc filed Critical Digital Gene Technologies Inc
Publication of EP1250431A2 publication Critical patent/EP1250431A2/de
Publication of EP1250431A4 publication Critical patent/EP1250431A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
EP01905039A 2000-01-25 2001-01-25 Modulierung der genexpression bei der bildung von fett-atherosklerotischen schädigungen Withdrawn EP1250431A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17796300P 2000-01-25 2000-01-25
US177963P 2000-01-25
PCT/US2001/002439 WO2001054651A2 (en) 2000-01-25 2001-01-25 Modulation of gene expression in formation of fatty atherosclerotic lesions

Publications (2)

Publication Number Publication Date
EP1250431A2 EP1250431A2 (de) 2002-10-23
EP1250431A4 true EP1250431A4 (de) 2004-08-11

Family

ID=22650638

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01905039A Withdrawn EP1250431A4 (de) 2000-01-25 2001-01-25 Modulierung der genexpression bei der bildung von fett-atherosklerotischen schädigungen

Country Status (4)

Country Link
EP (1) EP1250431A4 (de)
AU (1) AU2001232958A1 (de)
CA (1) CA2398563A1 (de)
WO (1) WO2001054651A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030065A1 (en) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
WO1997030065A1 (en) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HELLER R A ET AL: "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, no. 94, pages 2150 - 2155, XP002076789, ISSN: 0027-8424 *
See also references of WO0154651A3 *
WANG XINKANG ET AL: "The use of mRNA differential display for discovery of novel therapeutic targets in cardiovascular disease", CARDIOVASCULAR RESEARCH, vol. 35, no. 3, September 1997 (1997-09-01), pages 414 - 421, XP002281448, ISSN: 0008-6363 *

Also Published As

Publication number Publication date
WO2001054651A2 (en) 2001-08-02
WO2001054651A3 (en) 2002-01-17
EP1250431A2 (de) 2002-10-23
CA2398563A1 (en) 2001-08-02
AU2001232958A1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
GB2366640B (en) Distribution of activation information
GB0016452D0 (en) Vitamin K and essential fatty acids
PL346262A1 (en) Stripable varnishes
IL153230A0 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
GB2367469B (en) Software definable pre-amplifier
AU5002301A (en) Cosmetic compositions comprising exfoliating enzymes and uses thereof
AU2001236916A1 (en) Techniques to facilitate shopping for projects
GB0018186D0 (en) Calculation of slip on grades
GB0006733D0 (en) Enzyme
AU2347002A (en) Modulation of the transcription of pro-inflammatory gene products
AU2001269123A1 (en) Regulation of human dipeptidyl-peptidase iv-like enzyme
AU2001264269A1 (en) Oily cosmetics and process for producing same
AU1497802A (en) Ss-thio-amino acids
AU2002230869A1 (en) Antisense modulation of hepsin expression
AU2002226099A1 (en) Branched reaction products of alcohols and aldehydes
EP1250431A4 (de) Modulierung der genexpression bei der bildung von fett-atherosklerotischen schädigungen
AU2452302A (en) Sunscreen formulations containing nucleic acids
AU2002230845A1 (en) Antisense modulation of hepsin expression
AU2001278979A1 (en) Integrated management of product information
GB2368157B (en) Byte-swapping for efficient use of memory
AU2001225011A1 (en) Inhibition of carbohydrate-modified enzymes in host organisms
TW421997U (en) Improved structure of heating oil ejector
AU2002219063A1 (en) Human triacylglycerol lipase
TW431180U (en) Structure for changing torque of cart
AU2002303122A1 (en) Drag reduction using fatty acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020806

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

19U Interruption of proceedings before grant

Effective date: 20040407

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20041102

A4 Supplementary search report drawn up and despatched

Effective date: 20040628

19W Proceedings resumed before grant after interruption of proceedings

Effective date: 20051004

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUROME, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060801